

Zai Lab to Announce Third Quarter 2022 Financial Results on November 9, 2022

October 18, 2022

-- Company to Host Conference Call and Webcast on November 10, 2022, at 8:00 a.m. ET

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that it will report financial results and corporate updates for the three months ended September 30, 2022, after the closing of the U.S. equity markets on November 9, 2022. The Company will host a live conference call and webcast on November 10, 2022, at 8:00 a.m. ET.

Conference Call and Webcast Information

Listeners may access the live webcast by visiting the Company's website at http://ir.zailaboratory.com. Participants must register in advance of the conference call. Details are as follows:

Registration Link: https://register.vevent.com/register/BI98db73679f254c8eb1024c9df5ea85a8

All participants must use the link provided above to complete the online registration process in advance of the conference call. Upon registering, each participant will receive a dial-in number, Direct Event passcode, and a unique access PIN, which can be used to join the conference call.

A replay will be available shortly after the call and can be accessed by visiting the Company's website at http://ir.zailaboratory.com.

About Zai Lab

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States focused on bringing transformative medicines for oncology, autoimmune disorders, infectious diseases, and neurological disorders to patients in China and around the world. Our goal is to leverage our competencies and resources to positively impact human health worldwide.

For additional information about Zai Lab, including our products, business activities and partnerships, research, and other events or developments, please visit <u>www.zailaboratory.com</u> and follow us at <u>www.twitter.com/ZaiLab_Global</u>.

For more information, please contact:

Investor Relations: Lina Zhang +86 136 8257 6943 lina.zhang@zailaboratory.com

Media: Christine Drury / Xiaoyu Chen +1 (317) 385-9227 / +86 185 0015 5011 christine.drury@zailaboratory.com / xiaoyu.chen@zailaboratory.com

Source: Zai Lab Limited



Source: Zai Lab Limited